Lupin has signed a strategic licensing agreement with US-based Romark Laboratories which grants Lupin exclusive rights to promote, distribute and market Alinia (nitazoxanide) for oral suspension in the US.
Alinia (nitazoxanide) is the first thiazolide approved by the FDA for the treatment of diarrhoea caused by Cryptosporidium and Giardia and is the only FDA-approved treatment for Cryptosporidium. Alinia for oral suspension is indicated for the treatment of diarrhoea caused by Giardia lamblia or Cryptosporidium parvum in patients one year of age and older. These are the two most common protozoal causes of diarrhoea in the developed and developing world.
Use of Alinia suspension in children is facilitated by relatively simple dosing and administration; a strawberry flavoured suspension given twice a day for three days (100mg BID for ages 1 – 3 and 200mg BID for ages four to 11).
Alinia for oral suspension will not only enable Lupin to strengthen its existing brand portfolio but also expand its offering specifically, but not limited to the US Paediatrics segment. Key prescribers for Alinia include paediatricians, paediatric, gastroenterologists and primary care physicians which are strategic customer groups for Lupin, so we are well positioned to capitalise on this opportunity. Lupin’s current 160+ strong brands sales force will promote Alinia for oral suspension in the US market. The product will be marketed along with Lupin’s Suprax and Antara.
“We are excited with the addition of Alinia for oral suspension to our brands portfolio. The agreement demonstrates Lupin’s commitment to grow its brand franchise in the US and bring meaningful products to the paediatric community. Our sales and marketing efforts will commence immediately and we are optimistic that Alinia will contribute to our growth and profitability in the coming quarters and years,” said Vinita Gupta, Chief Executive Officer, Lupin Pharmaceuticals and Group President, Lupin.
EP News Bureau – Mumbai
- Advertisement -
